Phase 3 Trials of Elafibranor and Seladelpar for Primary Biliary Cholangitis. Reply

N Engl J Med. 2024 May 30;390(20):1935-1936. doi: 10.1056/NEJMc2403986.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antipruritics* / therapeutic use
  • Clinical Trials, Phase III as Topic
  • Humans
  • Liver Cirrhosis, Biliary* / complications
  • Liver Cirrhosis, Biliary* / drug therapy
  • Pruritus* / drug therapy
  • Pruritus* / etiology

Substances

  • 2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid
  • seladelpar
  • Antipruritics